Home › NCT04150614

BMT-08: A Comparative Effectiveness Study of Transdermal Granisetron to Ondansetron

BMT-08: A Comparative Effectiveness Study of the Efficacy and Safety of Transdermal Granisetron to Ondansetron in the Prevention of Nausea and Vomiting in Patients Undergoing Preparative Chemotherapy and Hematopoietic Stem Cell Transplantation

Who can join

Ages 18 to 75 · All sexes

Inclusion Criteria:

* Age 18-75 years at time of enrollment receiving either a preparative regimen and either an autologous or allogeneic stem cell transplant.
* No vomiting ≤ 24 hours prior to registration
* No treatment with an antipsychotic agent such as risperidone, quetiapine, clozapine, phenothiazine or butyrophenone for ≤ 30 days' prior registration or planned during protocol therapy. No patients will be removed from these treatments for study enrollment purposes.
* No chronic phenothiazine administration as an antipsychotic agent (patients may receive prochlorperazine and other phenothiazines as rescue antiemetic therapy). No patients will be removed from these treatments for study enrollment purposes.
* No known hypersensitivity to granisetron

Exclusion Criteria:

* Concurrent use of amifostine
* Known hypersensitivity to granisetron patch or ondansetron
* Patients with a history of long QT syndrome or Torsade de Pointes

About the study

Patients undergoing either an autologous or allogeneic hematopoietic stem cell transplant (HSCT) and receiving preparative chemotherapy experience a considerable amount of chemotherapy-induced nausea and vomiting (CINV). Current strategies at reducing CINV in this patient population are suboptimal due to lack of efficacy and supportive evidence, potential for increased adverse events, and drug-drug and drug-disease contraindications.

What is being tested

• Granisetron Transdermal Patch (drug)
• Intravenous Dexamethasone (drug)
• Ondansetron (drug)

Sponsor: University of Illinois at Chicago · Participants: 90 · Started: May 14, 2020

Contact the study team

• Karen Sweiss, PharmD · Phone: 312-996-0875

Official record on ClinicalTrials.gov — NCT04150614

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.